Ryan Mee, CEO of Fulcrum Metals, reviews FY23 and progress on the Gold Tailings Hub in Canada. Watch the video here.
Markets move to a change in economic drivers, ie Interest rate rise in UK. Significant share prices movement is in proportion to the rate of exposure to these economic indicators, directly or indirectly.
FUM is a news driven share (at the minute) so a sharp drop in the SP at end of the trading session is puzzling.
" Imagine the publicity worldwide at that point. Passed two separate trials, over the counter, day time tv and magazines will love it."
It is clear that the markets have very low confidence in the BoD (probably for good reason), hence the current SP.
I also have reminded myself that FUM is a small R&D company, who now appear to be positioning themselves to be driving the manufacturing, marketing and sales of Eroxon, no small feat. That is why I am convinced that subject to FDA approval this story will change entirely. Whether the BoD are architects of this change (which I am hoping they are bevering away to achieve, every minute of the day) or they are subjected to hostile T/O, the SP should ignite.
Whilst not a fan of the current BoD by any means, I can see why they would not want to telegraph any business sensitive information, especially as a T/O might be on the cards.
I am satisfied that Lambard Odi are still on board and 72.28 of company is owned by large managers/investors. The brokers have seen something to raise the price target . General public only holds 26% (possible reason for not doing a running commentary.)
Been LTH and happy to wait out the final stages. Nothing is risk free in life, however trial success confirms it works and to required level for marketing OTC.
Totally DE risked now. All of FDA set endpoints are met. FDA approval should be a formality. CE mark in the bag. SP was higher on announcement of FDA trials then it is today. The market for OTC device, with no side effects are enormous. T/O has got to be the best way to market. Although not expecting any big announcements in the intrems, a timely RSN wouldn't be out of the question, in my view.
Everything now hinges upon the outcome of US trials. I believe reason for your point (1).
I also believe that a correct outcome will lead to a takeover, as your point (5) implies, historically this management does not boast track record of any successful launches. This could potentially get too big for them to handle. If it is what we expect, it will require an existing infrastructure ready to roll. However, your point (4) would be of concern to any potential multinational considering a takeover. I am guessing the existing licensing deals will contain force majeure 'takeover' clause.
Around about now the 'punters' will be piling in, hype on BB gets intense, the MM's get even more shifty and the potential to lose one's shirt gets even greater. This is AIM, not every thing that glitters will turn to gold. Yes, the outlook is bright and potential great, however, remember the rule of AIM, 'only invest what you can afford to comfortably lose'.
I am fully expecting some activity in the SP in lead up to the FDA outcome, typical of the movemnet just prior to CE mark. I have to restrain my self from adding, as we all know, nothing in life a given. If all goes as expected I can see a spike in the price, however, i will be happy to buy into it as the big buying will come later when general media get hold of the story. Just my thoughts.
Judging by some comments being made on this board, it appears that 'punters' are getting anxious and restless. I am sure the management are not silent to spite these people.
Let's be clear, We are here to make money, and some are here to make quick money none of us are here because we wish to support the company.
Usually, companies' feedback to large stake holders (Hedge funds, pension funds...) or via broker presentations. (Not price sensitive information, which comes in an RSN format) None of us fit the 'large stake holder' status.
All the groundwork in anticipation of the co-ordinated launch and US partner should be happening now, hence, the silence, I believe. The stuff will sell itself when (If!) the FDA approval comes. I am baffled by the level of current SP.
I could not see any point of launching a product which has not had a 'proper rubber stamp'. (As strenuously argued at length with the resident basher, a CE mark is not an absolute proof of successful trial.)
When results from FD71 - FDA study are released in "...Eary September...", the media marketing should automatically be triggered. I am convinced that company marketing launch and ambient marketing is planned to complement this. Obviously, subject to the study confirming the current results. I see the SP strengthening in lead up to this.
Fuzz: understood. I can appreciate and empathise with all LTH,s. While researching FUM prior to investing, I remember making a note in my pros/cons about poor management of previous products, by the Co.
. I only overlooked the past due to my belief in the potential of this product. While I have not been invested as long as some, I am in it long term. I do believe that if this takes off, it will keep going and also, this BoD will not be the ones driving it.
You have just acquired a house that may have belonged to Shakespeare. This could make it into a tourist trap and could generate substantial income. Along with your own findings, a local expert has confirmed that it is likely to be true. Now a higher authority in US is examining the issue and should report in around three months.
What should you do?
a) Sell up now, as seen, to local interest?
b) Start selling visitor tickets, in hope that international crowds will buy into the local expert finding?
c) Hold off and await the expert confirmation, while lining up ticketing outlets for the local market. Ticketing outlets for lucrative US market should follow after the confirmation.
“Our doubts are traitors and make us lose the good we oft might win by fearing to attempt.”
-WS
One does not have to be in marketing to appreciate the importance of a timely launch. The BoD have had a few false starts, so I am guessing they are committed to getting it right this time. We have to accept that the BoD are in control and driving it according to their learning curve. Perhaps a coordinated launch (?)
I trust the product more than the BoD. It is what it is!
"Even limited success in these larger markets could transform Futura Medical, in our view."
- Trinity Delta